0.67
-0.049(-6.81%)
Currency In USD
| Previous Close | 0.72 |
| Open | 0.73 |
| Day High | 0.74 |
| Day Low | 0.65 |
| 52-Week High | 2.38 |
| 52-Week Low | 0.53 |
| Volume | 390,375 |
| Average Volume | 618,365 |
| Market Cap | 32.53M |
| PE | -0.41 |
| EPS | -1.62 |
| Moving Average 50 Days | 0.73 |
| Moving Average 200 Days | 1.16 |
| Change | -0.05 |
If you invested $1000 in Werewolf Therapeutics, Inc. (HOWL) since IPO date, it would be worth $41.63 as of February 21, 2026 at a share price of $0.67. Whereas If you bought $1000 worth of Werewolf Therapeutics, Inc. (HOWL) shares 3 years ago, it would be worth $216.19 as of February 21, 2026 at a share price of $0.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Werewolf Therapeutics Announces Pipeline and Business Updates
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profileWTX-330 Phase 1b/2 tria
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mous
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
GlobeNewswire Inc.
Oct 08, 2025 12:00 PM GMT
Fast Track Designation underscores the promise of Werewolf’s INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), pioneering the development of therapeutics